Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus neoadjuvant cisplatin/docetaxel for resectable NSCLC
ACTRN12608000061336Phase 2Not yet recruiting
- Sponsor
- Austin Health
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Austin Health. Primary endpoint: Pathologic response rate. Planned start Feb 2008; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12608000061336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000061336.